Yarrow Bioscience, Inc. (YARW)
NASDAQ: YARW · Real-Time Price · USD
25.54
-0.53 (-2.03%)
Sep 25, 2026, 4:00 PM EDT - Market closed
Company Description
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
The company’s candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves’ disease and thyroid eye disease.
The company was incorporated in 2025 and is based in New York, New York.
Yarrow Bioscience, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Rebecca Velez Frey |
Contact Details
Address: 40 10 th Avenue, Floor 7 New York, New York 10014 United States | |
| Website | yarrowbioscience.com |
Stock Details
| Ticker Symbol | YARW |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1566044 |
| CUSIP Number | 92941V407 |
| ISIN Number | US92941V4077 |
| Employer ID | 45-3757789 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rebecca Velez Frey Pharm.D. | President, Chief Executive Officer and Director |
| Tyler Zeronda CPA | Chief Financial Officer |
| Rachael Alford Ph.D. | Chief Operating Officer |
| Dr. Lori Payton Ph.D. | Chief Development Officer |
| Dr. Steven W. Ryder F.A.C.P, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 17, 2026 | SCHEDULE 13G | Filing |
| Sep 14, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 424B5 | Filing |
| Sep 11, 2026 | 424B5 | Filing |
| Sep 10, 2026 | 8-K | Current Report |
| Aug 19, 2026 | EFFECT | Notice of Effectiveness |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 13, 2026 | 8-K/A | [Amend] Current report |